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Abstract
Introduction A healthcare-associated infection (HAI)
data point prevalence study (PPS) conducted in 1984 in
Australian hospitals estimated the prevalence of HAI to be
6.3%. Since this time, there have been no further national
estimates undertaken. In the absence of a coordinated
national surveillance programme or regular PPS, there is
a dearth of national HAI data to inform policy and practice
priorities.
Methods and analysis A national HAI PPS study will be
undertaken based on the European Centres for Disease
Control method. Nineteen public acute hospitals will
participate. A standardised algorithm will be used to detect
HAIs in a two-stage cluster design, random sample of
adult inpatients in acute wards and all intensive care unit
patients. Data from each hospital will be collected by two
trained members of the research team. We will estimate
the prevalence of HAIs, invasive device use, single room
placement and deployment of transmission-based
precautions.
Ethics and dissemination Ethics approval was obtained
from the Alfred Health Human Research Ethics Committee
(HREC/17/Alfred/203) via the National Mutual Assessment.
A separate approval was obtained from the Tasmanian
Health and Medical Human Research Committee
(H0016978) for participating Tasmanian hospitals. Findings
will be disseminated in individualised participating hospital
reports, peer-reviewed publications and conference
presentations.

Introduction
Surveillance of healthcare-associated infections (HAIs) is a fundamental component
of any infection prevention programme.1
National HAI point prevalence studies (PPS)
provide a ‘snapshot’ of all HAI types and are
used to identify priority areas for action and
inform infection prevention recommendations and policy direction.2 Many European

Strengths and limitations of this study
►► The study is based on validated methods within the

European Centres for Disease Control point prevalence study surveillance protocol, with the addition
of device use prevalence estimates.
►► Data from all sites will be collected by two trained
data collectors minimising variation between sites.
►► Restriction to adult acute inpatients in public facilities limits representativeness.
►► Some infections may be missed due to sampling
process.

countries regularly contribute HAI data to
the European Centres for Disease Control
(ECDC) PPS surveillance, and this is often in
addition to existing, well-established national
HAI surveillance programmes.3 4
Australia’s first and only HAI PPS was
conducted in 1984 and estimated the prevalence of ‘nosocomial’ infections to be
6.5%.5 Subsequently, many local HAI surveillance programmes have evolved separately,
resulting in broad variation in activity and
methodology to the extent that data cannot
be reliably collated to generate national
Australian HAI data, with the exception of
Staphylococcus aureus bacteraemia.6–8
Despite strong support for a national
surveillance programme,9 there has been
no funding identified to achieve this goal.
This means that Australian national infection prevention policy is not informed by
sound national data, nor can national interventions be effectively evaluated. Further,
where existence of HAI surveillance occurs
at local hospital or State level, variations in
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Study objectives
The primary objectives of the CHAINS study are
1. To estimate the total prevalence of HAIs among inpatients aged ≥18 in public acute care hospitals in
Australia.
2. To describe the HAIs by site, type of patient, specialty,
type of facility and geographical location.
The secondary objectives are
1. To determine the prevalence of patients
a. Managed under transmission-based precautions isolation in a single room.
b. With an indwelling urinary catheter device.
c. With vascular access device(s).
d. With a multidrug-resistant organism (infection or
colonisation).
Methods and analysis
Study design
A rolling PPS across a sample of Australian public hospitals will be undertaken over a 3-month period. The PPS
protocol is based on the ECDC standardised methodology for PPSs on HAIs,10 with some modifications to the
Standard Protocol option (see below and table 1). The
ECDC protocol was developed and tested extensively with
reliable outcomes. It has been used across 29 European
countries for national PPS and has also been applied in
several non-European countries.11–13
Hospital selection
Public acute care hospitals categorised as a Principal
Referral hospital or a Group A hospital as per the Australian Institute for Health and Welfare peer groupings will
2

be eligible to participate.14 These two peer groups are
characterised by providing a broad range of services,
include emergency and intensive care units (ICUs), and
have larger patient volumes than other peer groups.14
Because of anticipated heterogeneity and to maximise representation of large acute care public facilities,
specialist hospitals (eg, maternity, cancer and paediatric
hospitals) and private hospitals will be excluded.
Limited resources for this PPS restricts the number of
participating hospitals to a sample of public acute care
facilities. We will launch a call for expressions of interest
for hospitals to participate in the study to measure the
appetite for participation. To best meet the objectives
of the study, 19 hospitals will be purposively selected to
participate from those who meet the selection criteria.
Hospital selection numbers will be approximately proportional to the size of the six States and one of Territories in
Australia (the other Territory will not be included due to
logistical reasons).
Ward selection
In each participating hospital, all acute care inpatient
wards will be included with the exception of
►► Paediatric wards.
►► Psychiatric wards (acute and non-acute).
►► Neonatal ICUs.
►► Rehabilitation, palliative, subacute and long-term
care wards in acute care facilities (eg, nursing homes,
spinal rehabilitation wards).
►► Accident and emergency (A&E) departments
(except for wards attached to A&E departments
where patients are monitored for more than
24 hours).
Patient sampling
Patients will be sampled in a two-stage cluster design,
with a sample of patients in a sample of Principal Referral
and Group A Hospitals. Patients will be systematically
sampled on each eligible ward at participating hospitals by randomly selecting either odd-numbered or
even-numbered beds (50% sample). Randomisation will
be achieved by the toss of a coin by the lead investigator
(PLR) prior to the research assistants (RAs) visiting each
site. If the bed is empty due to it not being used, then
this is not counted in the denominator, and the next bed
occupied within the random sample will be surveyed. As a
high-risk group of interest, all patients in adult ICUs will
be surveyed.
We estimate that we will survey 50% of patients at
19 hospitals (estimated up to 5000 patients total).
Assuming an intracluster correlation coefficient of
3% and a prevalence of hospital acquired infection of
7.5%–10%, we will be able to estimate prevalence with
a precision of ±2.2%–2.5% (based on the 95% CI).
Estimates of prevalence will account for the clustered
design and oversampling in ICU (using inverse probability weighting).
Russo PL, et al. BMJ Open 2018;8:e024924. doi:10.1136/bmjopen-2018-024924
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methodologies means that it is not possible to meaningfully aggregate data.
We will undertake the first Australian HAI PPS in over
30 years, the Comprehensive Healthcare Associated
Infection National Surveillance (CHAINS) study. The
European protocol provides a standardised methodology
to European Member States and hospitals. The current
version 5.3 provides a framework to develop a PPS in
Australia.3 While based on the protocol developed by the
ECDC, the CHAINS protocol differs in a number of areas
including participation and recruitment criteria, and
does not include patient-level risk factors or antimicrobial
prescribing data.
The purpose of this study is to update our knowledge
on the prevalence of HAIs and multidrug-resistant organisms in Australia and provide stakeholders with national
benchmarks that can be used to identify areas for improvement, measure effectiveness of interventions and importantly use as a model for future national surveillance
activities. We will also determine the prevalence of device
use, informing future research projects and providing
useful data for industry.
While guidelines for describing PPS protocols have not
been published, this paper describes the study protocol
and focuses on areas that vary from the ECDC protocol.

Open access

ECDC protocol

Deviations

Rationale

Patient inclusion and exclusion
►► All patients admitted to the ward
►► 50% patients in acute wards and all
before or at 08:00 and not discharged
intensive care unit patients
from the ward at the time of survey,
►► Only adults ≥18 years old admitted to
including neonates on maternity and
the ward before or at 08:00 and not
paediatric wards, will be included
discharged from the ward at the time of
survey will be included

►► Insufficient resources to sample

every patient

Data collection processes
►► Composition of the team responsible

for data collection varied from one
hospital to another

►► The same data collectors will be

collecting data for all hospitals in the
PPS

►► To minimise variation and maximise

consistency in classifying infections

►► Minimise the burden of data

collection on participating hospitals

►► Total time frame for data collection for ►► Data to be collected during a one-off

all wards of a single hospital did not
exceed 2 to 3 weeks

hospital visit (1–3 days)

►► Same data collectors used across

all facilities

►► Smaller sample size

Patient data fields
►► McCabe score was employed to

►► No risk factor data will be collected

►► Insufficient resources to collect risk

►► Antimicrobial use

►► No antimicrobial use data will be

►► Antimicrobial data already collected

classify the severity of underlying
medical conditions

collected

factor data

in annual point prevalence survey

Data validation
►► Recommended sample size at the

►► Records of 100% of patients identified

►► Validation team consisted was

►► Validation team members will consist of

national level was 750 patients in 25
hospitals

separate from the original data
collection team
►► Blinded data validation
recommended

►► Same data collectors used across
as having an infection at the first hospital
all facilities
(up to a maximum of 40) and a random
►► Pragmatic validation within existing
sample of 5% of those identified as not
resources
having an infection will be reviewed

the chief investigators who cross-check
the data
►► Validation team will not be blinded

►► Same data collectors used across

all facilities

►► Not practical for this study

ECDC, European Centres for Disease Control; PPS, point prevalence study.

Patient selection
Consistent with the ECDC protocol, in each ward meeting
the above inclusion criteria, all patients admitted to the
ward before or at 08:00 on the first survey day and not
discharged from the ward at the time of the survey will be
eligible. In practice, this means that patients transferred in
or out after 08:00 of the first survey day from or to another
ward, or location outside the hospital, will not be included.
Patients who meet the following criteria on the eligible
wards will be excluded:
►► Patients under 18 years of age (in any hospital ward
or unit).
►► Patients undergoing same day treatment or surgery.
►► Patients seen at outpatient department.
►► Patients in the emergency room.
►► Dialysis patients (outpatients).
Data collection and management
Data collection from 19 sites across Australia will occur
over a 3-month period from August to October 2018. A
Russo PL, et al. BMJ Open 2018;8:e024924. doi:10.1136/bmjopen-2018-024924

specific date for each hospital visit will be coordinated
with the hospital. The location and size of the facility will
be considered when planning visits to maximise efficiency
of data collection.
All data will be collected by two trained RAs. As a
condition of enrolment in the study, hospitals will be
required to provide a hospital-based clinician, preferably a member of the infection prevention team, on the
survey days. The role of the hospital clinician will be to
accompany the RAs and to facilitate access to all wards
and data.
The two RAs will be trained by the research team in
data collection methodology and use of data collection
tools. The RAs will also undergo competency-based assessment prior to data collection. A secure online web-based
survey tool will be accessed for data entry.
We will collect four levels of data: hospital, ward, patient
and HAI.
3
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Table 1 Summary of major differences in protocol
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Ward data
Ward demographic data will be collected on the day of
the survey. Data on the ward specialty, total number of
beds and number of single rooms are the same as for
ECDC. Different to ECDC protocol will be data collected
on the number of patients placed in single room isolation
and the type of isolation. No other ward level data will be
collected.
Patient data
Patient-level data is a modified version of the ECDC Standard Protocol. Two main differences are the omission of
both risk factor data (McCabe) score and antimicrobial
use data. The omission of risk factor data is to ensure
patient data can be collected in a timely manner. Detailed
antimicrobial data were omitted given that Australia has
an annual national antimicrobial prescribing PPS, which
allows more thorough analysis of antimicrobial use in
Australia than what was possible in this PPS.15 As a screen
to determine the presence of a HAI, data on the presence of fever and current antimicrobial therapy will be
collected.
Data on the presence of a multidrug-resistant organism
(MRO) will also be collected. These will include
►► MRSA: methicillin-resistant S. aureus.
►► VRE: vancomycin-resistant enterococci.
►► ESBL: extended-spectrum β-lactamase.
►► CPE: carbapenemase-producing Enterobacteriaceae.
►► Clostridium difficile.
►► Other drug-resistant gram-negative organisms.
►► Other organisms that have been identified by the
hospital as an MRO.
Screening for colonisation will occur according to
local protocols by participating hospitals. The prevalence
of colonisation will therefore represent colonisation
as detected according to current Australian infection
prevention practices. We will report on the local screening
practices to assist with interpretation of the prevalence of
colonisation.
HAI data
For each patient with a fever or currently receiving antimicrobial therapy, the RAs will work through an algorithm
applying the HAI definitions in the ECDC protocol. Data
on each HAI identified will be consistent with the ECDC
protocol.
4

Data validation
Data will be assessed for completeness and accuracy at
the first hospital to undergo the survey. Records of 100%
of patients identified as having an infection (up to a
maximum of 40) and a random sample of 5% of those
identified as not having an infection will be reviewed by
two chief investigators. Findings will be discussed with the
research team prior to the survey proceeding.
Data analysis
The prevalence of HAI will be estimated from the
proportion with infection in the sample (correcting for
oversampling of ICU patients) with CIs corrected for
the clustered design. This will be performed using the
svy module in Stata V.14.2 (StataCorp, College Station,
Texas, USA). The analysis will consider each hospital as a
cluster and adjust for oversampling in ICU using inverse
probability weights. Logistic regression will be used to
examine factors associated with infection. These factors
will include
►► Location of hospital: metro, remote and so on.
►► Age.
►► Gender.
►► Ward type.
►► Intubation.
►► Presence of peripheral vascular access device.
►► Presence of central vascular access device.
►► Indwelling urinary catheter.
Outcome measures
The outcomes for each objective of the study are outlined
in table 2.
Ethical considerations
The National Mutual Assessment is a system of single
scientific and ethical review of multicentre human
research projects in public health organisations in Australian Capital Territory, New South Wales, Queensland,
South Australia, Victoria and Western Australia.
Any risks or harms identified and associated with the
study will be reported to the human research ethics
committees (HRECs). Reporting of the study and progress, including audits, will be conducted consistent with
the requests of the HRECs. Any modification to the study
that have ethical implications will be forwarded to the
HRECs for approval. In the main results paper for the
study, we will also aim to estimate the resources required
to obtain ethics approval and site-specific authorisations.
Informed consent
A waiver of individual patient consent has been obtained
for this study from the HRECs based on a number of
considerations. These considerations are as follows:
there are no interventions and no harm or discomfort
to the patient as a result of the project; the benefits of
the research justify any risk of harm associated with not
obtaining consent; results of the research are not individualised or indeed patient identifiable; the study requires
no direct involvement of patients, rather it collates
Russo PL, et al. BMJ Open 2018;8:e024924. doi:10.1136/bmjopen-2018-024924
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Hospital data
General hospital demographic data will be collected
based on the ECDC protocol. However, the only indicator
data similar to ECDC protocol are data on hand hygiene
compliance and the number of infection control full time
effective nurses. Further indicator data to be included
are S. aureus bacteraemia rates (routinely reported to
the Australian Health and Institute of Welfare) and ICU
central line-associated bloodstream infection rates if available. These data will be collected prior to the visit.

Open access

Objective

Outcome measure

Primary objectives
To estimate the total prevalence of HAIs among
Total no of patients classified as having a HAI divided by the total no of
inpatients aged ≥18 in public acute care hospitals in patients surveyed, weighted by the probability of sampling
Australia
To describe the HAIs by site, type of patient,
specialty, type of facility and geographical location

Of the patients with a HAI, the proportion by
►► Infection site
►► Elective or emergency
►► Gender
►► Age
►► Ward specialty
►► Facility type

Secondary objectives
Prevalence of patients managed under
Total no of patients cared for under transmission-based precautions
transmission-based precautions isolation in a single divided by the total number of patients surveyed, overall (weighted by the
room
probability of sampling), by hospital, by ward specialty
Prevalence of patients with an indwelling urinary
catheter device

Total no of patients with a urinary catheter divided by the total no of
patients surveyed, overall, by hospital, by ward specialty

Prevalence of patients with vascular access
device(s)

Total no of patients with a vascular access device divided by the total
no of patients surveyed
Of those with a vascular device, the proportion by type of device, overall,
by hospital, by ward specialty
Total no of patients infected or colonised with a multidrug-resistant
organism divided by the total no of patients surveyed
Of those with a multidrug-resistant organism, the proportion by organism,
overall, by hospital, by ward specialty

Prevalence of patients with a multidrugresistant organism (infection or colonisation)

HAI, healthcare-associated infection.

existing information obtained during their hospitalisation; and no new information will be obtained about individual patients, therefore results will have no significance
for the individual welfare of patients.
Patient and public involvement statement
There was no patient or public involvement in the development of this study; however, the study was reviewed
by patient and consumer representatives on the HREC.
While results will not be provided directly to the patients
surveyed in the study, data will be provided back to each
participating facility and policy representatives and
disseminated through peer-reviewed publications and
conferences.
Dissemination
Dissemination of knowledge gained from this study will
be facilitated using a variety of modes. Each participating
hospital will be provided with an individualised report
highlighting their outcomes in comparison with other
hospitals (deidentified) and aggregated data. Overall
study findings will be presented through peer-reviewed
publications, presentations to jurisdictional policy representatives and relevant conferences.
Discussion
There is a dearth of national HAI data in Australia. Data
from a multicentre PPS on urinary tract infections in
Russo PL, et al. BMJ Open 2018;8:e024924. doi:10.1136/bmjopen-2018-024924

Australia estimated the HAI rate of urinary tract infection
(UTI) was 1.4% and the catheter-associated UTI prevalence to be 0.9%.16 Recently, an estimate of the burden
of HAI in Australia was generated from a systematic
review of studies published between 2010 and 2016 and
suggested the incidence of HAIs in Australia may be up
to 165 000 per year.17
Although the Australian Commission for Safety and
Quality in Health Care has a number of national initiatives to prevent HAI, it can be argued that these initiatives
may be misdirected given the lack of national HAI data
to inform and evaluate interventions. While administrative data will soon be used to measure HAIs in Australia,18
we contend that HAI surveillance cannot be adequately
performed with this approach.19 20
The importance of reliable national HAI data in
Australia cannot be underestimated. The CHAINS study
is a small first step towards an improved understanding of
the prevalence of HAIs in Australia. To identify, develop,
implement and evaluate national HAI initiatives, reliable
data based on validated methods must be used.
Strengths
This study has a number of strengths. First, it is based on
established and validated methodology from the ECDC.
Second, rather than rely on each hospital to collect
and submit data, which is the common process in large
5
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Limitations
Data collection is limited to adult acute inpatients, no
data are being collected from hospitals within the private
sector, and to ensure timely collection of data at each
site, patient-level risk factor data (ie, McCabe index data)
are not being collected. Some active HAIs may be missed
due to the random sampling of patients and the use of
fever or current antimicrobial therapy as a screen to
explore the presence of HAI.
As hospitals were purposively selected rather than a
random sample, we cannot exclude selection bias. To
examine this, we will compare administrative and infection prevention metrics of participating hospitals with
those of non-participating hospitals in the same peer categories. Such metrics will include state/territory location,
remoteness area, bed numbers, presence of high-risk
units for HAIs (eg, oncology, bone marrow transplantation and solid-organ transplantation), healthcare-associated S. aureus bloodstream infection rate (cases per
10 000 bed days) and hand hygiene compliance.
Study status
Data collection is due to commence in August 2018.
Author affiliations
1
School of Nursing and Midwifery, Faculty of Health, Centre for Quality and Patient
Safety Research—Alfred Health Partnership, Deakin University, Melbourne, Victoria,
Australia
2
Department of Infectious Diseases, Alfred Health and Monash University,
Melbourne, Victoria, Australia
3
Infection Prevention and Healthcare Epidemiology Unit, The Alfred Hospital,
Melbourne, Victoria, Australia
4
School of Public Health and Preventive Medicine, Monash University, Melbourne,
Victoria, Australia
5
Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore
6
National Centre for Infectious Diseases, Singapore
7
Yong Loo Lin School of Medicine, National University of Singapore, Singapore
8
Faculty of Arts, Nursing and Theology, Avondale College of Higher Education,
Wahroonga, New South Wales, Australia
Acknowledgements The authors acknowledge the work of the CHAINS Project
Manager, Bridey Saultry, and the key stakeholders at potential sites; and the Centre
for Quality and Patient Safety, Deakin University, for supporting and administering
the project. We also acknowledge Professor Jacqui Reilly and Professor Jennie
Wilson for expert advice and guidance in the planning stages of this project.
Contributors Five authors (PLR, AS, ACC, TB, BGM) are chief investigators and are
involved in the design and implementation of the study. KM has provided expert
advice on national point prevalence surveys and provided access to data collection

6

tools and educational materials. PLR prepared the manuscript, and all other authors
contributed sections, critiqued and revised and approved the manuscript.
Funding This project is wholly funded by the Rosemary Norman Foundation, a
philanthropic nursing charity that has funded in excess of US$1 million into nursing
and midwifery research over the last decade.
Disclaimer None of the researchers receive any income from the funding or have
any role with the charity. The Foundation was not involved in the design nor the
conduct of the study, and will not benefit in any form from the results of the study.
Competing interests None declared.
Patient consent Not required.
Ethics approval Alfred Health.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the use
is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Perl TM, Chaiwarth R. Surveillance: an overview. In: Lautenbach E,
Woeltje KF, Malani PN, eds. Practical healthcare epidemiology. 3rd
edn. London: The University of Chicago Press, 2010:111–42.
2. Cairns S, Gibbons C, Milne A, et al. Results from the third Scottish
National prevalence survey: is a population health approach now
needed to prevent healthcare-associated infections? J Hosp Infect
2018;99:312–7.
3. European Centre for Disease Prevention and Control. Point
prevalence survey of healthcare-associated infections and
antimicrobial use in European acute care hospitals—protocol version
5.3. Stockholm: ECDC, 2016.
4. Russo PL, Cheng AC, Richards M, et al. Healthcare-associated
infections in Australia: time for national surveillance. Aust Health Rev
2015;39:37–43.
5. McLaws ML, Gold J, King K, et al. The prevalence of nosocomial and
community-acquired infections in Australian hospitals. Med J Aust
1988;149:582–90.
6. Russo PL, Barnett AG, Cheng AC, et al. Differences in identifying
healthcare associated infections using clinical vignettes and the
influence of respondent characteristics: a cross-sectional survey of
Australian infection prevention staff. Antimicrob Resist Infect Control
2015;4:1–7.
7. Russo PL, Cheng AC, Richards M, et al. Healthcare-associated
infections in Australia: time for national surveillance. Australian Health
Review 2015;39:37–43.
8. Russo PL, Cheng AC, Richards M, et al. Variation in health careassociated infection surveillance practices in Australia. Am J Infect
Control 2015;43:773–5.
9. Russo PL, Chen G, Cheng AC, et al. Novel application of a discrete
choice experiment to identify preferences for a national healthcareassociated infection surveillance programme: a cross-sectional
study. BMJ Open 2016;6:e011397.
10. European Centre for Disease Prevention and Control. Point prevalence
survey of healthcare associated infections and antimcrobial use in
European acute care hospitals. Stockholm: ECDC, 2013.
11. Phu VD, Wertheim HF, Larsson M, et al. Burden of hospital acquired
infections and antimicrobial use in Vietnamese adult intensive care
units. PLoS One 2016;11:e0147544.
12. Morioka H, Hirabayashi A, Iguchi M, et al. The first point prevalence
survey of health care–associated infection and antimicrobial use in
a Japanese university hospital: a pilot study. Am J Infect Control
2016;44:e119–23.
13. Cai Y, Venkatachalam I, Tee NW, et al. Prevalence of healthcareassociated infections and antimicrobial use among adult inpatients
in Singapore acute-care hospitals: results from the first national point
prevalence survey. Clin Infect Dis 2017;64:S61–7.
14. Australian Institute for Health and Welfare. Australian hospital peer
groups. Health services series no. 66. Cat. no. HSE 170. Canberra:
AIHW, 2015.
15. National Centre for Antimicrobial Stewardship and Australian
Commission on Safety and Quality in Health Care. Antimicrobial
prescribing practice in Australian hospitals: results of the 2015
National Antimicrobial Prescribing Survey. Sydney: ACSQHC, 2016.

Russo PL, et al. BMJ Open 2018;8:e024924. doi:10.1136/bmjopen-2018-024924

BMJ Open: first published as 10.1136/bmjopen-2018-024924 on 8 November 2018. Downloaded from http://bmjopen.bmj.com/ on 9 November 2018 by guest. Protected by copyright.

PPS studies, this study will use the same trained and
competent data collectors at each hospital. This greatly
increases the likelihood of consistency in data collection and application of HAI definitions and prevents
any subjective influences that may occur at a hospital
level. Third, the two-stage cluster design, randomised
sampling of patients at each facility and the inclusion of
facilities in six of the seven Australian jurisdictions will
provide confident estimates of the prevalence of HAI.
Fourth, data on the prevalence of device use, single
room placement and transmission-based precautions
have never before been estimated in Australia and will
generate new knowledge.

Open access

Russo PL, et al. BMJ Open 2018;8:e024924. doi:10.1136/bmjopen-2018-024924

gov.au/our-work/indicators/hospital-acquired-complications/
(accessed 20 Apr 2018).
19. Mitchell BG, Ferguson JK. The use of clinical coding data for the
surveillance of healthcare-associated urinary tract infections in
Australia. Infection, Disease & Health 2016;21:32–5.
20. van Mourik MS, van Duijn PJ, Moons KG, et al. Accuracy of
administrative data for surveillance of healthcare-associated
infections: a systematic review. BMJ Open 2015;5:e008424.

7

BMJ Open: first published as 10.1136/bmjopen-2018-024924 on 8 November 2018. Downloaded from http://bmjopen.bmj.com/ on 9 November 2018 by guest. Protected by copyright.

16. Gardner A, Mitchell B, Beckingham W, et al. A point prevalence
cross-sectional study of healthcare-associated urinary tract
infections in six Australian hospitals. BMJ Open 2014;4:e005099.
17. Mitchell BG, Shaban RZ, MacBeth D, et al. The burden of healthcareassociated infection in Australian hospitals: a systematic review of
the literature. Infection, Disease & Health 2017;22:117–28.
18. Australian Commission for Safety and Quality in Health Care.
Hospital-acquired complications. 2018 https://www.safetyandquality.

